ContributorsPublishersAdvertisers

Companies Enter Licensing Agreements to Expand Gene Therapy Programs

biospace.com
 2021-10-12

Cover picture for the articleDays after forging a $1.1 billion agreement with Selecta Biosciences to develop gene therapies for lysosomal storage disorders, Takeda Pharmaceutical entered into a licensing pact with Poseida Therapeutics for its Cas-CLOVER nanoparticle delivery technology and other genetic engineering platforms. The deal is worth up to $3.6 billion. Takeda intends...

www.biospace.com

Comments / 0

Comments / 0